{"result": "(\"entity\"<|>NURIA VALDES GALLEGO<|>PERSON<|>Nuria Valdes Gallego is a specialist in Endocrinology and Nutrition, licensed in Biochemistry and holds a doctorate in Medicine. She is the head of the Endocrinology and Nutrition Section at the University Hospital of Cabueñes in Gijón and an associate professor of Endocrinology.)\n##\n(\"entity\"<|>HOSPITAL UNIVERSITARIO DE CABUEÑES<|>ORGANIZATION<|>The University Hospital of Cabueñes is a medical facility in Gijón where Nuria Valdes Gallego works as the head of the Endocrinology and Nutrition Section.)\n##\n(\"entity\"<|>FENILCETONURIA<|>EVENT<|>Phenylketonuria is a genetic disorder caused by the deficiency of phenylalanine hydroxylase, leading to high levels of phenylalanine in the blood, which can cause serious health issues if not managed properly.)\n##\n(\"entity\"<|>EMBRIOPATÍA FENILPIRÚVICA<|>EVENT<|>Maternal phenylketonuria or phenylpiruvic embryopathy occurs in fetuses of mothers who maintain high levels of phenylalanine during pregnancy, leading to potential teratogenic effects.)\n##\n(\"relationship\"<|>NURIA VALDES GALLEGO<|>HOSPITAL UNIVERSITARIO DE CABUEÑES<|>Nuria Valdes Gallego is the head of the Endocrinology and Nutrition Section at the University Hospital of Cabueñes in Gijón.<|>8)\n##\n(\"relationship\"<|>FENILCETONURIA<|>EMBRIOPATÍA FENILPIRÚVICA<|>Phenylketonuria can lead to maternal phenylketonuria or phenylpiruvic embryopathy if not managed during pregnancy.<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de si el feto padece la enfermedad o tiene la alteración\n         relación causal.       Por tanto, la hiperuricemia se puede considerar un marcador de riesgo                                            genética.\n         cardiovascular y su        hallazgo debe intensificar en el paciente las              medidas     de   prevención                       La concentración sérica elevada de fenilalanina durante el embarazo temprano en una ma-\n         cardiovascular. No obstante, la hiperuricemia no se puede considerar un verdadero factor                                                dre con fenilcetonuria o hiperfenilalaninemia, con niveles de fenilalanina constantes su-\n         de riesgo cardiovascular, porque su tratamiento no ha demostrado reducir eventos.                                                       periores a 360 µmol/l (6 mg/dl), puede dar lugar a embriopatía por fenilalanina, por lo que\n         Referencias:                                                                                                                            se deben mantener por debajo de dichos niveles, idealmente antes de la concepción, o al\n         • Burns CM, Wortmann RL. Trastornos del metabolismo de las purinas y pirimidinas. En: Kasper et al. eds. Cap. 431. Harrison Principios  menos antes de las 10 semanas de gestación. Por tanto, hay que planificar la gestación\n           de Medicina Interna. 19.ª ed. McGrawHill; 2015. Disponible en: http://highered.mheducation.com/sites/dl/premium/6071513359/           llegando al embarazo con niveles seguros, y evitar situaciones como la descrita en la pre-\n           student/1079317/Part16_Ch431e_p001_p007.pdf#toolbar=0                                                                                 gunta, que supera ampliamente el rango de seguridad.\n                                                                                                                                                 La tetrahidrobiopterina (BH4) es un cofactor de las hidroxilasas de fenilalanina, tirosina y\n     45  En el síndrome de PKU materna o embriopatía fenilpirúvica, ¿cuál de las siguientes                                                      triptófano. La sapropterina es un preparado sintético de la BH4. Está indicada en el trata-\n         no es una característica clínica?                                                                                                       miento de la fenilcetonuria leve, asociado al tratamiento dietético apropiado para limitar la\n                                                                                                                                                 cantidad de fenilalanina. Hay un grupo de pacientes respondedor, y otro no respondedor,\n         A. Retraso mental.                                                                                                                      por lo que es necesario un ensayo terapéutico y un ajuste de dosis según los niveles de\n         B. Macrocefalia.                                                                                                                        fenilalanina en sangre, suspendiéndolo en caso de falta de respuesta. La sapropterina se\n         C. Malformaciones cardiacas.                                                                                                            puede usar en niños a partir de los 4 años y adultos, pero no en la gestación por la falta de\n         D.  Alteraciones faciales.                                                                                                              experiencia en humanos, aunque no se haya observado toxicidad reproductiva en animales\n                                                                                                                                                 (categoría C de la FDA). Solo cabría plantear su uso en caso de gestación si es estricta-\n     46  ¿La sapropterina en el embarazo está catalogada como fármaco clase?                                                                     mente necesario porque no se consigan resultados suficientes de fenilalanina con la dieta.\n         A. A.                                                                                                                                   Referencias:\n                                                                                                                                                 • Bodamer OA. Overview of phenylketonuria. Hahn S, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.\n         B. B.                                                                                                                                     (Last updated: Dec 03, 2018.)\n         C. C.\n         D.  D.\n     47  Acude sin cita a nuestra consulta una paciente con fenilcetonuria porque se ha\n         quedado embarazada, una gestación sin planificar, con unos niveles de fenilalanina\n         plasmáticos de 580 µmol/l (9,5 mg/dl). ¿Cuáles son los niveles de fenilalanina\n         plasmáticos que se consideran teratogénicos durante la gestación?\n         A. >610 µmol/l (10 mg/dl).\n         B. >970 µmol/l (16 mg/dl).\n         C. >120 µmol/l (2 mg/dl).\n         D.  >360 µmol/l (6 mg/dl).\n\n\n\n         COMENTARIO\n         La fenilcetonuria resulta de la deficiencia de fenilalanina-hidroxilasa. La embriopatía fe-\n         nilpirúvica o fenilcetonuria materna ocurre en fetos de madres que mantienen niveles\n\n\n\n368                                                                                                                                                                                                                                                                     369\n---\nNO_CONTENT_HERE\n---\nMÓDULO                              Metabolismo fosfocálcico,\n       7                        tumores neuroendocrinos\n                            y MEN\n\n\n\n          AUTORA\n          Nuria Valdes Gallego\n             Especialista en Endocrinología y Nutrición. Licenciada en Bioquímica y doc-\n             tora en Medicina. Jefa de Sección de Endocrinología y Nutrición del Hospital\n             Universitario de Cabueñes, Gijón. Profesora asociada de Endocrinología y\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}